M&A is not the only area of the market that may see opportunities in 2024.
M&A is not the only area of the market that may see opportunities in 2024. John Montana, CEO at Calluna Pharma said companies on the brink of reaching clinical Proof-of-Concept within their current funding round might be good candidates for IPO, assuming the market is favorable. “Additionally, strategic alignment with diseases of high pharma interest opens doors for licensing opportunities providing access to non-dilutive funding and potential acquisition,” Montana added.